

**NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Oxidronic Acid 99mTc-Complex. [Updated 2023 Oct 15].


Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/



## **Oxidronic Acid 99mTc-Complex**

Revised: October 15, 2023.

CASRN: 72945-61-0



# **Drug Levels and Effects**

## **Summary of Use during Lactation**

Information in this record refers to the use of oxidronic acid 99mTc-complex (Tc99m-hydroxymethylene diphosphonate; Tc99m-HDP) as a diagnostic agent. A US Nuclear Regulatory Commission subcommittee has recommended that nursing be discontinued for 24 hours after administration of all technetium Tc 99m diagnostic products to simplify guidance recommendations, although this time interval may be longer than necessary.[1] Other sources state that breastfeeding need not be interrupted after administration of Tc 99m HDP to nursing mothers.[2] However, to follow the principle of keeping exposure "as low as reasonably achievable", some experts recommend nursing the infant just before administration of the radiopharmaceutical and interrupting breastfeeding for 3 to 6 hours after the dose, then expressing the milk completely once and

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

discarding it or store it for at least 60 hours (10 half-lives) before giving it to the infant. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[2-5]

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level, she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[6]

For nursing mothers who work with Tc 99m substances in their workplace, there is no need to take any precautions other than those appropriate for general radiation protection.[7]

## **Drug Levels**

Tc 99m is a gamma emitter with a principal photon energy of 140 keV and a physical half-life of 6.04 hours.[1] The effective half-life of Tc 99m HDP is 5.1 hours.[2]

#### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

#### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

#### References

- Dilsizian V, Metter D, Palestro C, Zanzonico P. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material. Final report submitted: January 31, 2019. 2019. Available at: https://www.nrc.gov/docs/ML1903/ ML19038A498.pdf
- 2. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: Data, quantitative analysis and recommendations. Nucl Med Commun 1989;10:15-27. PubMed PMID: 2645546.
- 3. Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St Louis Mosby-Year Book, Inc 1995:1380-1.
- 4. International Atomic Energy Agency. Radiation Protection and Safety in Medical Uses of Ionizing Radiation, IAEA Safety Standards Series No. SSG-46, IAEA, Vienna. 2018. Available at: https://www.iaea.org/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation
- 5. ARSAC notes for guidance: Good clinical practice in nuclear medicine. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2020. Available at: https://www.gov.uk/government/publications/arsac-notes-for-guidance
- 6. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. J Nucl Med 2000;41:863-73. PubMed PMID: 10809203.
- 7. Almén A, Mattsson S. Radiological protection of foetuses and breast-fed children of occupationally exposed women in nuclear medicine Challenges for hospitals. Phys Med 2017;43:172-7. PubMed PMID: 28882410.

## **Substance Identification**

### **Substance Name**

Oxidronic Acid 99mTc-Complex

# **CAS Registry Number**

72945-61-0

# **Drug Class**

Breast Feeding

Lactation

Milk, Human

Radiop harm aceuticals

Technetium Compounds

Diagnostic Agents